Trial Results: ECOG-ACRIN Research Round-Up

News in Brief image

News in Brief, November 2026

November 19, 2026

Amended Trial: Lova Sun Describes Important Changes to the EA3231 Study for Patients With BRAF-Mutated Differentiated Thyroid Cancer

November 19, 2026
News in Brief image

News in Brief, November 2026

November 19, 2026

Amended Trial: Lova Sun Describes Important Changes to the EA3231 Study for Patients With BRAF-Mutated Differentiated Thyroid Cancer

November 19, 2026

Trial Results: ECOG-ACRIN Research Round-Up

Research definition

Below are summaries of recent publications involving ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) researchers and trial data. The publications relate to cancer clinical trials in leukemia, pancreas cancer, and throat cancer. Click on the shortened citations to access the publications.

Leukemia – Could leukemia’s genetic features help explain treatment response? Researchers analyzed genetic and clinical information from 569 adults registered for ECOG-ACRIN’s E1910 trial to understand why patients respond differently to treatment. They identified 23 genetic subtypes of B-cell acute lymphoblastic leukemia (B-ALL). Adding blinatumomab, an immunotherapy drug, to chemotherapy appeared to help patients with several subtypes live longer and remain free of leukemia longer than chemotherapy alone. Larger studies are needed to confirm these findings and determine how they could guide treatment. Genomic Drivers of Leukemia and Blinatumomab Response in Adult Acute Lymphoblastic Leukemia - the ECOG-ACRIN E1910 Study. Zhong X. Blood. October 2026.

Pancreas Cancer – Pancreatic adenocarcinoma is a devastating disease for which there are limited treatment options. ECOG-ACRIN researchers designed the phase 1/phase 2 study EA2131 to test whether adding adavosertib, a Wee1 inhibitor, to chemotherapy (nab-paclitaxel/gemcitabine) could improve treatment. This publication reports on seven patients with metastatic or locally advanced, unresectable pancreatic adenocarcinoma who received the combination during phase 1. The combination was too toxic to proceed to the planned phase 2 portion. A Phase I Study of Nab-Paclitaxel, Gemcitabine and AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas: ECOG-ACRIN EA2131. Eads JR. Clin Colorectal Cancer. September 2026.

Throat Cancer – Could a swallowing test before surgery identify patients who need extra support? Swallowing problems are common after surgery for HPV-related throat cancer. Researchers reviewed swallowing X-rays taken before and after surgery in 89 participants in ECOG-ACRIN’s E3311 trial. Even mild swallowing problems before surgery were linked to a higher risk of moderate-to-severe problems afterward. The findings suggest that pre-surgery testing could help identify patients who may benefit from swallowing exercises, nutrition support, and closer follow-up. Prognostic Value of Baseline Modified Barium Swallow for Perioperative Dysphagia in Oropharyngeal Cancer: Secondary Analysis of ECOG-ACRIN E3311. Manduchi B. Oral Oncol. November 2026.

Throat Cancer – Could lowering radiation doses reduce lasting side effects? Radiation for HPV-related throat cancer can cause problems with swallowing, dry mouth, and voice changes. Researchers analyzed patient questionnaires from ECOG-ACRIN’s E2399 trial and its follow-up trial, E1308. Patients who received lower-dose radiation in E1308 reported fewer problems with swallowing, dry mouth, voice, and neck and shoulder movement at 6 months. Questionnaires designed for head and neck cancer detected differences that general quality-of-life surveys missed. These findings could help future trials measure whether treatment changes reduce patients’ symptoms. Patient-Reported Toxicity With Radiation Deintensification in Human Papillomavirus–Associated Oropharynx Cancer: ECOG-ACRIN E2399 and E1308. Cmelak AJ. JCO Oncol Adv. September 2026.

Leave a Reply

Your email address will not be published. Required fields are marked *

Please DO NOT include personal medical information, diagnoses, treatment details, medical record numbers, or other sensitive health information in this form.